OFIX

SEC source: 0001209191-18-038641 · doc4.xml · nonDerivative · entry 4

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,844

F2 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.01 to $59.13, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-038641 · doc4.xml · nonDerivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,569

F2 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.01 to $59.00, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-038641 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

SEC source: 0001209191-18-038641 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

SEC source: 0001209191-18-038018 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,221

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.84 to $58.20, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-028212 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,613

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.73 to $52.00, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-18-023313 · doc4.xml · derivative · entry 3

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,616

Underlying: Common Stock · 4,616 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023313 · doc4.xml · derivative · entry 2

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,193

Underlying: Common Stock · 8,193 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023313 · doc4.xml · nonDerivative · entry 1

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,352

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023309 · doc4.xml · derivative · entry 3

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,055

Underlying: Common Stock · 5,055 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023309 · doc4.xml · derivative · entry 2

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,973

Underlying: Common Stock · 8,973 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023309 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,972

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023302 · doc4.xml · derivative · entry 3

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,396

Underlying: Common Stock · 4,396 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023302 · doc4.xml · derivative · entry 2

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,803

Underlying: Common Stock · 7,803 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023302 · doc4.xml · nonDerivative · entry 1

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,257

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023291 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,055

Underlying: Common Stock · 5,055 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023291 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,973

Underlying: Common Stock · 8,973 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023291 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,296

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023279 · doc4.xml · derivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,715

Underlying: Common Stock · 5,715 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023279 · doc4.xml · derivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,144

Underlying: Common Stock · 10,144 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023279 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,794

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023263 · doc4.xml · derivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,385

Underlying: Common Stock · 7,385 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023263 · doc4.xml · derivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,109

Underlying: Common Stock · 13,109 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023263 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,870

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023268 · doc4.xml · derivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,814

Underlying: Common Stock · 6,814 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023268 · doc4.xml · derivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,095

Underlying: Common Stock · 12,095 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023268 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,790

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023260 · doc4.xml · derivative · entry 3

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,102

Underlying: Common Stock · 37,102 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023260 · doc4.xml · derivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,857

Underlying: Common Stock · 65,857 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023260 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,572

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-019207 · doc4.xml · derivative · entry 1

SICARD JOHN · CIK 0001734027 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2028-03-12

F1 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, March 12, 2018.

SEC source: 0001209191-17-065473 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,631

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.85 to $52.51, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-17-063033 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,053

SEC source: 0001209191-17-059756 · doc4.xml · nonDerivative · entry 1

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,729

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.57, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-17-052629 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,103

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.65 to $49.75, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-17-052626 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,178

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $49.81, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-17-052617 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,743

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.16 to $49.685, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-17-050387 · doc4.xml · nonDerivative · entry 1

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,127

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.21 to $48.33, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-17-049973 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,053

SEC source: 0001209191-17-048784 · doc4.xml · nonDerivative · entry 1

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,084

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-17-044661 · doc4.xml · derivative · entry 3

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,881

Underlying: Common Stock · 4,881 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044661 · doc4.xml · derivative · entry 2

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,516

Underlying: Common Stock · 8,516 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044661 · doc4.xml · nonDerivative · entry 1

GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,332

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044662 · doc4.xml · derivative · entry 3

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,881

Underlying: Common Stock · 4,881 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044662 · doc4.xml · derivative · entry 2

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,516

Underlying: Common Stock · 8,516 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044662 · doc4.xml · nonDerivative · entry 1

FUJIKAWA RAYMOND · CIK 0001669831 · President Spine Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,448

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044660 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,965

Underlying: Common Stock · 5,965 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044660 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,409

Underlying: Common Stock · 10,409 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044660 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,134

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044659 · doc4.xml · derivative · entry 3

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,965

Underlying: Common Stock · 5,965 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.